The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.

There are >24 million registered adult donors, and the numbers of unrelated donor transplantations are increasing. The optimal strategy for prioritizing among comparably HLA-matched potential donors has not been established. Therefore, the objective of the current analyses was to study the association between donor characteristics (age, sex, parity, cytomegalovirus serostatus, HLA match, and blood group ABO match) and survival after transplantation for hematologic malignancy. The association of donor characteristics with transplantation outcomes was examined using either logistic or Cox regression models, adjusting for patient disease and transplantation characteristics associated with outcomes in 2 independent datasets: 1988 to 2006 (N = 6349; training cohort) and 2007 to 2011 (N = 4690; validation cohort). All donor-recipient pairs had allele-level HLA typing at HLA-A, -B, -C, and -DRB1, which is the current standard for selecting donors. Adjusting for patient disease and transplantation characteristics, survival was better after transplantation of grafts from young donors (aged 18-32 years) who were HLA matched to recipients (P < .001). These findings were validated for transplantations that occurred between 2007 and 2011. For every 10-year increment in donor age, there is a 5.5% increase in the hazard ratio for overall mortality. Increasing HLA disparity was also associated with worsening survival. Donor age and donor-recipient HLA match are important when selecting adult unrelated donors. Other donor characteristics such as sex, parity, and cytomegalovirus serostatus were not associated with survival. The effect of ABO matching on survival is modest and must be studied further before definitive recommendations can be offered.

[1]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[2]  J. Wagner,et al.  The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  Loren Gragert,et al.  HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. , 2014, The New England journal of medicine.

[4]  D. Cox Regression Models and Life-Tables , 1972 .

[5]  J. Klein,et al.  Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. , 2009, Blood.

[6]  Robert N. Stavins,et al.  ENVIRONMENTAL REGULATION IN THE 1990 S : A RETROSPECTIVE ANALYSIS , 2003 .

[7]  R. Vij,et al.  Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. , 2015, Blood.

[8]  J. Wagner,et al.  Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  Harriet Noreen,et al.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. , 2007, Blood.

[10]  M. Hirokawa,et al.  Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program , 2008, Haematologica.

[11]  J. Wingard,et al.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.

[12]  M. Maiers,et al.  Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  John P. Klein,et al.  Discretizing a Continuous Covariate in Survival Studies , 2003, Advances in Survival Analysis.

[14]  J. Klein,et al.  HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  Richard A. Miller The Aging Immune System: Primer and Prospectus , 1996, Science.

[16]  C Anasetti,et al.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. , 2001, Blood.

[17]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[18]  H. Einsele,et al.  Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  K. Schwarz,et al.  High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. , 2013, Blood.

[20]  Medhat Askar,et al.  Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. , 2014, Blood.

[21]  J. Wagner,et al.  Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. , 2010, The Lancet. Oncology.

[22]  R. Brand,et al.  Female‐Versus‐Male Alloreactivity as a Model for Minor Histocompatibility Antigens in Hematopoietic Stem Cell Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  K. Sullivan,et al.  Pathophysiology and treatment of graft-versus-host disease. , 1999, Hematology/oncology clinics of North America.

[24]  Brent R Logan,et al.  A perspective on the selection of unrelated donors and cord blood units for transplantation. , 2012, Blood.

[25]  R. Brand,et al.  Risk score for outcome after allogeneic hematopoietic stem cell transplantation , 2009, Cancer.

[26]  A. Gratwohl The EBMT risk score , 2012, Bone Marrow Transplantation.